Publications 2019-04-09T09:49:14+00:00

Bitto, A., et al., Activation of the EPOR-beta common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochim Biophys Acta Mol Basis Dis, 2018. 1864(2): p. 632-639
Bohr, S., et al., Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proc Natl Acad Sci U S A, 2013. 110(9): p. 3513-8.
Bohr, S., et al., Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. J Mol Med (Berl), 2015. 93(2): p. 199-210.
Brines M, Dunne AN, van Velzen M,et al. (2014) ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014; 20: 658-666.
Brines M, Patel NS, Villa P, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008; 105: 10925-10930.
Collino M, Benetti E, Rogazzo M, et al. (2014) A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol. 2014; 171: 5802-5815.
Collino M, Thiemermann C, Cerami A, Brines M. (2015) Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015; 151: 32-40.
Culver, D.A., et al., Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci, 2017. 58(6): p. BIO52-BIO60.
Dahan A, Dunne A, Swartjes M, et al. (2013) ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013; 19: 334-345.
Hache, G., et al., ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing Ability. Shock, 2016. 46(4): p. 390-7.
McVicar CM, Hamilton R, Colhoun LM, et al. (2011) intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 2011; 60: 2995-3005.
Muller, C., et al., ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Mol Med, 2016. 21(1): p. 969-978
Nairz, M., et al., Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep, 2017. 7(1): p. 13012.
Patel NS, Kerr-Peterson HL, Brines M, et al. (2012) Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012; 18: 719-727.
Pulman KG, Smith M, Mengozzi M, Ghezzi P, Dilley A. (2013) The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience. 2013; 233: 174-183.
Robertson, C.S., et al., Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock. J Neurotrauma, 2012. 29(6): p. 1156-66.
Robertson, C.S., et al., Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide. J Neurotrauma, 2013. 30(9): p. 765-74.
Schmidt RE, Feng D, Wang Q, et al. (2011) Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol. 2011; 232: 126-135.
Swartjes M, Morariu A, Niesters M, et al. (2011) ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology. 2011; 115: 1084-1092.
Swartjes, M., et al., Ketamine does not produce relief of neuropathic pain in mice lacking the beta-common receptor (CD131). PLoS One, 2013. 8(8): p. e71326.
Swartjes M, van Velzen M, Niesters M, et al. (2014) ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014; 10: 13.
Ueba, H., et al., Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A, 2010. 107(32): p. 14357-62.
Ueba, H., et al., Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin. Mol Med, 2013. 19: p. 195-202.
Watanabe M, Lundgren T, Saito Y, et al (2015) A nonhematopoietic erythropoietin analogue, ARA 290, inhibits macrophage activation and prevents damage to transplanted islets. Transplantation. 2015;100:554-562. 
Zhang, W., G. Yu, and M. Zhang, ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides, 2016. 76: p. 73-9.